Ignite Creation Date:
2025-12-25 @ 3:48 AM
Ignite Modification Date:
2026-01-13 @ 5:25 PM
Study NCT ID:
NCT02563002
Status:
COMPLETED
Last Update Posted:
2024-10-03
First Post:
2015-09-28
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-11-30
Start Date Type:
ACTUAL
Primary Completion Date:
2021-02-19
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-07-17
Completion Date Type:
ACTUAL
First Submit Date:
2015-09-28
First Submit QC Date:
None
Study First Post Date:
2015-09-29
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2022-01-06
Results First Submit QC Date:
None
Results First Post Date:
2022-03-16
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-09-18
Last Update Post Date:
2024-10-03
Last Update Post Date Type:
ACTUAL